{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:56:19Z","timestamp":1789005379213,"version":"build-2803163510"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ceftolozane\/tazobactam and ceftazidime\/avibactam are commonly used in patients with MDR-Pseudomonas aeruginosa (PSA) pneumonia (PNA). This study compared outcomes between non-COVID-19 hospitalized patients with MDR-PSA PNA who received ceftolozane\/tazobactam or ceftazidime\/avibactam.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study included non-COVID-19 adult hospitalized patients with MDR-PSA PNA in the PINC AI Healthcare Database (2016\u201322) who received ceftolozane\/tazobactam or ceftazidime\/avibactam within 3\u2005days of index culture for \u22652\u2005days. Outcomes were mortality, recurrent MDR-PSA PNA, discharge destination, post-index culture day length of stay (LOS) and costs (in US dollars, USD), and hospital readmission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The final sample included 197 patients (117 ceftolozane\/tazobactam, 80 ceftazidime\/avibactam). No significant differences were observed in mortality and post-index culture LOS and costs between groups. In the multivariable analyses, patients who received ceftolozane\/tazobactam versus ceftazidime\/avibactam had lower recurrent MDR-PSA PNA (7.9% versus 18.0%, P\u200a=\u200a0.03) and 60\u2005day PNA-related readmissions (11.1% versus 28.5%, P\u200a=\u200a0.03) and were more likely to be discharged home (25.8% versus 9.8%, P\u200a=\u200a0.03). Compared with ceftazidime\/avibactam patients, ceftolozane\/tazobactam patients had lower adjusted median total antibiotic costs (5052 USD versus 8099 USD, P\u200a=\u200a0.003) and lower adjusted median comparator (ceftolozane\/tazobactam or ceftazidime\/avibactam) antibiotic costs (3938 USD versus 6441 USD, P\u200a=\u200a0.005). In the desirability of outcome ranking (DOOR) analysis, a ceftolozane\/tazobactam-treated patient was more likely to have a more favourable outcome than a ceftazidime\/avibactam-treated patient [DOOR probability: 59.6% (95% CI: 52.5%\u201366.8%)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Early treatment with ceftolozane\/tazobactam may offer some clinical and cost benefits over ceftazidime\/avibactam in patients with MDR-PSA PNA. Further large-scale studies are necessary to comprehensively understand the outcomes associated with these treatments for MDR-PSA PNA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae313","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T22:22:57Z","timestamp":1726093377000},"page":"2954-2964","source":"Crossref","is-referenced-by-count":17,"title":["Comparative evaluation of early treatment with ceftolozane\/tazobactam versus ceftazidime\/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P","family":"Lodise","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences , 106 New Scotland Avenue, Albany, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engels N","family":"Obi","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , 2025 E Scott Ave, Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre H","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , 2025 E Scott Ave, Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yucel","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , 2025 E Scott Ave, Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Min","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , 2025 E Scott Ave, Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H","family":"Nathanson","sequence":"additional","affiliation":[{"name":"OptiStatim LLC , 25 Willow Circle, Longmeadow, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"2024110323533981200_dkae313-B1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"2024110323533981200_dkae313-B2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","article-title":"Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012-2019","volume":"50","author":"Zilberberg","year":"2022","journal-title":"Crit Care Med"},{"key":"2024110323533981200_dkae313-B3","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024110323533981200_dkae313-B4","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B5","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024110323533981200_dkae313-B6","first-page":"78","article-title":"Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy","volume":"31","author":"Mensa","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"2024110323533981200_dkae313-B7","article-title":"Antibiotic Resistance Threats in the United States, 2019","author":"CDC","year":"2019"},{"key":"2024110323533981200_dkae313-B8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024110323533981200_dkae313-B9","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015\u201317)","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024110323533981200_dkae313-B10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024110323533981200_dkae313-B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B12","author":"AbbVie."},{"key":"2024110323533981200_dkae313-B13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024110323533981200_dkae313-B14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024110323533981200_dkae313-B15","author":"Merck Sharp & Dohme LLC"},{"key":"2024110323533981200_dkae313-B16","doi-asserted-by":"publisher","first-page":"106744","DOI":"10.1016\/j.ijantimicag.2023.106744","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020\u20132021)","volume":"61","author":"Sader","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2024110323533981200_dkae313-B17","doi-asserted-by":"publisher","first-page":"e0018922","DOI":"10.1128\/aac.00189-22","article-title":"In vitro activity of ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators against Pseudomonas aeruginosa isolates collected in United States hospitals according to results from the SMART surveillance program, 2018 to 2020","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323533981200_dkae313-B18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jgar.2020.04.017","article-title":"Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum beta-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres","volume":"22","author":"Hirsch","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2024110323533981200_dkae313-B19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/avibactam versus polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2024110323533981200_dkae313-B21","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Vena","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13756-021-00933-8","article-title":"Real-world use of ceftolozane\/tazobactam: a systematic literature review","volume":"10","author":"Puzniak","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"2024110323533981200_dkae313-B23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/antibiotics11050626","article-title":"The comparative effectiveness of ceftolozane\/tazobactam versus aminoglycoside- or polymyxin-based regimens in multi-drug-resistant Pseudomonas aeruginosa infections","volume":"11","author":"Caffrey","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024110323533981200_dkae313-B24","doi-asserted-by":"publisher","first-page":"e0040523","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323533981200_dkae313-B25","doi-asserted-by":"publisher","first-page":"ofac492.115","DOI":"10.1093\/ofid\/ofac492.115","article-title":"1649. Ceftolozane-tazobactam or ceftazidime-avibactam versus best available therapy in the treatment of difficult-to-treat Pseudomonas aeruginosa infections: a retrospective comparative effectiveness analysis of 195 U.S. hospitals, 2016\u20132020","volume":"9","author":"Lawandi","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024110323533981200_dkae313-B26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/phar.2446","article-title":"Impact of incremental delays in appropriate therapy on the outcomes of hospitalized adult patients with Gram-negative bloodstream infections: \u201cevery day matters\u201d","volume":"40","author":"Lodise","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2024110323533981200_dkae313-B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjms.2018.11.009","article-title":"Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious Gram-negative bacterial infections","volume":"357","author":"Bonine","year":"2019","journal-title":"Am J Med Sci"},{"key":"2024110323533981200_dkae313-B28","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1128\/AAC.00338-07","article-title":"Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323533981200_dkae313-B29","article-title":"PINC AI\u2122 Healthcare Data White Paper: Data that informs and performs.","author":"PINC AI\u2122 Applied Sciences, Premier Inc","year":"2021"},{"key":"2024110323533981200_dkae313-B30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/phar.2600","article-title":"Outcomes of adult patients in the intensive care unit with Pseudomonas aeruginosa pneumonia who received an active anti-pseudomonal beta-lactam: does \u201cS\u201d equal success in the presence of resistance to other anti-pseudomonal \u03b2-lactams?","volume":"41","author":"Lodise","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2024110323533981200_dkae313-B31","author":"Federal Reserve Bank of Minneapolis"},{"key":"2024110323533981200_dkae313-B32","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","article-title":"Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation","volume":"8","author":"Evans","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"2024110323533981200_dkae313-B34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B35","doi-asserted-by":"publisher","first-page":"e1157","DOI":"10.1093\/cid\/ciac692","article-title":"Improving traditional registrational trial end points: development and application of a desirability of outcome ranking end point for complicated urinary tract infection clinical trials","volume":"76","author":"Howard-Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B36","doi-asserted-by":"publisher","first-page":"S699","DOI":"10.1093\/ofid\/ofab466.1411","article-title":"1219. Unfavorable clinical outcomes with polymyxins compared to ceftolozane\/tazobactam for the treatment of carbapenem-resistant Pseudomonas aeruginosa","volume":"8","author":"Howard-Anderson","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024110323533981200_dkae313-B37","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2307\/2531493","article-title":"Distribution-free confidence intervals for a parameter of Wilcoxon-Mann- Whitney type for ordered categories and progressive censoring","volume":"45","author":"Halperin","year":"1989","journal-title":"Biometrics"},{"key":"2024110323533981200_dkae313-B39","article-title":"Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment","author":"FDA","year":"2014"},{"key":"2024110323533981200_dkae313-B40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00134-014-3563-6","article-title":"Mortality is the only relevant outcome in ARDS: no","volume":"41","author":"Kress","year":"2015","journal-title":"Intensive Care Med"},{"key":"2024110323533981200_dkae313-B41","doi-asserted-by":"publisher","first-page":"S534","DOI":"10.1097\/CCM.0b013e3181f208ac","article-title":"We should abandon randomized controlled trials in the intensive care unit","volume":"38","author":"Vincent","year":"2010","journal-title":"Crit Care Med"},{"key":"2024110323533981200_dkae313-B42","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/CCM.0b013e318168ea3e","article-title":"Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail?","volume":"36","author":"Ospina-Tasc\u00f3n","year":"2008","journal-title":"Crit Care Med"},{"key":"2024110323533981200_dkae313-B43","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(95)90733-5","article-title":"Morbidity or mortality as endpoint for clinical trials in intensive care","volume":"345","author":"Decruyenaere","year":"1995","journal-title":"Lancet"},{"key":"2024110323533981200_dkae313-B44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(95)90347-X","article-title":"Should morbidity replace mortality as an endpoint for clinical trials in intensive care?","volume":"345","author":"Petros","year":"1995","journal-title":"Lancet"},{"key":"2024110323533981200_dkae313-B45","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1097\/CCM.0000000000004000","article-title":"Which multicenter randomized controlled trials in critical care medicine have shown reduced mortality? A systematic review","volume":"47","author":"Santacruz","year":"2019","journal-title":"Crit Care Med"},{"key":"2024110323533981200_dkae313-B46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.respe.2011.08.067","article-title":"Kenneth J. Rothman and multicausality in epidemiology","volume":"60","author":"Bizouarn","year":"2012","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2024110323533981200_dkae313-B47","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ajic.2014.02.013","article-title":"Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis","volume":"42","author":"Bogan","year":"2014","journal-title":"Am J Infect Control"},{"key":"2024110323533981200_dkae313-B48","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1128\/AAC.50.4.1257-1262.2006","article-title":"Clinical and economic impact of bacteremia with extended- spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"50","author":"Schwaber","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323533981200_dkae313-B49","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1086\/529190","article-title":"Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia","volume":"46","author":"Jenkins","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B50","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/phar.2449","article-title":"Approach to the treatment of patients with serious multidrug-resistant Pseudomonas aeruginosa infections","volume":"40","author":"O\u2019Donnell","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2024110323533981200_dkae313-B51","doi-asserted-by":"publisher","first-page":"e0206721","DOI":"10.1128\/aac.02067-21","article-title":"Selection of AmpC \u03b2-lactamase variants and metallo-\u03b2-lactamases leading to ceftolozane\/tazobactam and ceftazidime\/avibactam resistance during treatment of MDR\/XDR Pseudomonas aeruginosa infections","volume":"66","author":"Ruedas-L\u00f3pez","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323533981200_dkae313-B52","doi-asserted-by":"publisher","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024110323533981200_dkae313-B53","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ijantimicag.2019.02.022","article-title":"Phylogenetic analysis of resistance to ceftazidime\/avibactam, ceftolozane\/tazobactam and carbapenems in piperacillin\/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients","volume":"53","author":"Zamudio","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024110323533981200_dkae313-B54","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/CCM.0000000000000897","article-title":"Can we make performance measures more resilient to the effects of coding?","volume":"43","author":"Lagu","year":"2015","journal-title":"Crit Care Med"},{"key":"2024110323533981200_dkae313-B55","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/M13-1419","article-title":"Variation in diagnostic coding of patients with pneumonia and its association with hospital risk-standardized mortality rates: a cross-sectional analysis","volume":"160","author":"Rothberg","year":"2014","journal-title":"Ann Intern Med"},{"key":"2024110323533981200_dkae313-B56","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/CCM.0000000000000862","article-title":"Gaming hospital-level pneumonia 30-day mortality and readmission measures by legitimate changes to diagnostic coding","volume":"43","author":"Sjoding","year":"2015","journal-title":"Crit Care Med"},{"key":"2024110323533981200_dkae313-B57","doi-asserted-by":"publisher","first-page":"ofab232","DOI":"10.1093\/ofid\/ofab232","article-title":"Effect of inadequate empiric antibacterial therapy on hospital outcomes in SARS-CoV-2-positive and -negative US patients with a positive bacterial culture: a multicenter evaluation from March to November 2020","volume":"8","author":"Puzniak","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2954\/60272191\/dkae313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2954\/60272191\/dkae313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T23:53:54Z","timestamp":1730678034000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/11\/2954\/7755014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,11]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae313","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,11]]}}}